Please select the option that best describes you:
Do you use Oncotype to determine the benefit of adjuvant chemotherapy in a male patient with breast cancer?
Do you consider it only in lymph-node negative or up to three lymph nodes?
Answer from: Medical Oncologist at Academic Institution
While there are fewer data, and no randomized data, what exists suggests that male breast cancer is comprised of a similar range of biologic entities, although the distributions may differ a little from female breast cancer. The question is timely; a recent JCO article (Massarweh et al, JCO 2018), e...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The data we just published looks at Recurrence Score (RS) testing in both men and women up to 3+ nodes. It appears that RS is prognostic in both men and women with regards to 5-year BCSS, with excellent outcomes at 5 years in 0-30 scores, so both low and intermediate, and regardless of nodal status ...